Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 2/20 | 0.48 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 4/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | GLS | O94925 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4686743 | 0.80 | JAK2 (0.44) | AXLNOS1JAK2JAK1GLS | |
| SCHEMBL19469912 | 0.75 | AXL (0.44) | AXLMETTL3NOS1JAK2JAK1 | |
| SCHEMBL29416146 | 0.75 | AXL (0.44) | AXLMETTL3NOS1JAK2JAK1 | |
| SCHEMBL19469910 | 0.75 | AXL (0.44) | AXLMETTL3NOS1JAK2JAK1 | |
| SCHEMBL20117005 | 0.74 | PARP1 (0.32) | — | |
| SCHEMBL13554518 | 0.72 | NOS1 (0.50) | AXLNOS1JAK2JAK1GLS | |
| SCHEMBL12166325 | 0.72 | IDO1 (0.51) | AXLNOS1JAK2JAK1GLS | |
| SCHEMBL29416223 | 0.72 | IDO1 (0.51) | AXLNOS1JAK2JAK1GLS | |
| SCHEMBL27663105 | 0.72 | NOS1 (0.50) | AXLNOS1JAK2JAK1GLS | |
| Bromide SCHEMBL27530305 | 0.71 | NOS1 (0.53) | AXLNOS1JAK2JAK1GLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3640251-B1 | 6,7,8,9-TETRAHYDRO-3H-PYRAZOLO[4,3-F]ISOQUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2021-12-08 | — | — | EP | disclosed |
| EP-3640251-A1 | 6,7,8,9-TETRAHYDRO-3H-PYRAZOLO[4,3-F]ISOQUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2020-04-22 | — | — | EP | disclosed |
| EP-3433256-B1 | 6,7,8,9-TETRAHYDRO-3H-PYRAZOLO[4,3-F]ISOQUINOLINE DERIVATIVE USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2019-08-07 | — | — | EP | disclosed |
| WO-2019002441-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2019-01-03 | — | — | WO | disclosed |
| WO-2018077630-A1 | 6,7,8,9-TETRAHYDRO-3H-PYRAZOLO[4,3-F]ISOQUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2018-05-03 | — | — | WO | disclosed |
| WO-2017182493-A1 | INDAZOLE DERIVATIVES FOR USE IN DOWN-REGULATION OF THE ESTROGEN RECEPTOR FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2017-10-26 | — | — | WO | disclosed |